Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04908280 · ClinicalTrials.gov registry record · Phase 2

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

A Phase 2 study, sponsored by University of Rochester.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target

NCT04908280: Completed Phase 2 study, sponsored by University of Rochester.

NCT04908280 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04908280, a Phase 2 study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target

Study Summary

The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

Primary Outcome

The Investigator's Global Assessment will be performed at study visits 2-6. The IGA is an instrument to rate the severity of the subject's global disease. This IGA is comprised of a 5-point scale of disease activity ranging from 0 to 4 as follows: 0: "clear," no erythema or scale 1. "almost clear," pink erythema without scale 2. "mild," pink erythema with scale 3. "moderate," red erythema with scale 4. "severe," purple/violaceous or hemorrhagic/crusted erythema OR hypertrophic/ verrucous scale

Interventions

  • DRUG Ruxolitinib

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-05-04
Est. Completion 2024-03-04
Phase Phase 2
University of Rochester

636 total trials

What the finished NCT04908280 record still lists

NCT04908280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.

NCT04908280 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04908280 about?

NCT04908280 is a clinical study titled "Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus". The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

What is the current status of trial NCT04908280?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-05-04. Estimated completion is 2024-03-04.

What interventions are being tested in trial NCT04908280?

The interventions under investigation include: Ruxolitinib (DRUG).

Who is sponsoring clinical trial NCT04908280?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04908280's enrollment target sits among peer trials

10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04908280, the US trial registry maintained by the National Library of Medicine. NCT04908280 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.